SLC19A1

Across TCGA pan-cancer cohorts, SLC19A1 RNA differs between tumor and matched normal tissue in 18 of 18 cancer types tested, making tumor–normal expression one of SLC19A1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SLC19A1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC19A1 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

BLCA, HNSC, and KIRC are the cancer types where SLC19A1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC19A1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	IV	+1.784	<.001	12	view →
HNSC	Male	III,IV	+1.431	<.001	12	view →
KIRC	Female	II,III,IV	+0.886	<.001	12	view →
THCA	Male	III,IV	−1.260	<.001	11	view →
COAD	All	III,IV	+1.079	<.001	11	view →
KIRP	All	II,III,IV	+0.831	<.001	11	view →
STAD	Male	II,III,IV	+1.535	<.001	10	view →
LUAD	Male	II,III,IV	−1.089	<.001	8	view →
UCEC	All	III,IV	+1.491	<.001	6	view →
LUSC	Male	All	−1.041	<.001	6	view →
BRCA	All	II,III,IV	+0.549	<.001	6	view →
READ	All	All	+1.217	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 18 lineages.

SLC19A1–BLCA

Open the BLCA breakdown →